An Open Trial to Assess the Tolerability of AVANZ Phleum Pratense Immunotherapy

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

199

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

March 31, 2012

Study Completion Date

April 30, 2012

Conditions
Allergic Rhinoconjunctivitis
Interventions
DRUG

AVANZ Phleum pratense

AVANZ Phleum pratense up-dosing phase (300, 600, 3000, 6000 and 15,000 SQ+) + one 15,000 SQ+ maintenance injection

Trial Locations (20)

10004

Hospital Nuestra Señora de La Montaña, Cáceres

10300

H. Campo Arañuelo, Cáceres

13500

Hospital Santa Bárbara, Puertollano

28006

Hospital Universitario de La Princesa, Madrid

28007

Hospital Gregorio Marañón, Madrid

28025

Fundación Jiménez Diaz, Madrid

28031

Hospital Infanta Leonor, Madrid

28342

Hospital Infanta Elena, Madrid

28922

Hospital Univesitario Fundación Hospital de Alcorcón, Madrid

29009

Hospital Carlos Haya, Málaga

34005

Hospital Rio Carrion, Palencia

37007

Hospital Universitario de Salamanca, Salamanca

39008

Hospital Univeritario Marques de Valdeilla, Santander

46026

Hospital Universitari Politecnic La Fe, Valencia

48013

Hospital de Basurto, Bilbao

49022

Hospital Virgen de La Concha, Zamora

05071

Hospital Nuestra Señora de Sonsoles, Ávila

06007

Hospital Universitario Infanta Cristina, Badajoz

09001

Complejo Hospitalario de Burgos, Burgos

01004

Hospital Santiago Apostol, Vitoria-Gasteiz

All Listed Sponsors
lead

ALK-Abelló A/S

INDUSTRY

NCT01454531 - An Open Trial to Assess the Tolerability of AVANZ Phleum Pratense Immunotherapy | Biotech Hunter | Biotech Hunter